Guildford, UK, 6 December 2005: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the Harris Nesbitt 5th Annual Investor Conference: Focus on Healthcare, scheduled for 8 December 2005 in New York City. Michael Hunt, Chief Executive Officer of ReNeuron, will give an overview of the Company’s activities and recent progress, and will participate in a panel discussion focusing on the state of the art in stem cell-based medicine, scheduled for 1:30pm EST on the day.

A webcast of the event will be available on ReNeuron’s website at, by clicking on the relevant links for this conference.

Notes to editors

ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by way of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

The Company’s lead stem cell therapy, ReN001 for chronic stroke disability, is in late pre-clinical development. The Company plans to file for approval to commence initial clinical trials in stroke by mid-2006, with trials commencing as soon as possible thereafter.

In addition to its ReN001 stroke programme, ReNeuron has programmes to develop stem cell therapies to address Huntington’s disease, Parkinson’s disease, Type 1 diabetes and diseases of the eye.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas – its ReNcellTM range of cell lines for use in drug discovery applications in the pharmaceutical industry.

The Company successfully completed its flotation on the London AIM market in August 2005, raising £9.5million before expenses. At flotation, the Company also issued warrants which, if exercised, will raise a further £5.7m for the Company by February 2007. ReNeuron’s shares are traded under the symbol RENE.L, and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at

Further information


Michael Hunt, Chief Executive Officer
Tel: +44 (0) 1483 302560

Financial Dynamics

David Yates
Sarah Macleod
Tel: +44 (0) 20 7831 3113

The terms “ReNeuron” or “the Company” refer to ReNeuron Group plc and its subsidiary undertakings.